Dr. Bellmunt Highlights Immunotherapy Options in Bladder Cancer
January 4th 2019Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.
Read More
Dr. Bellmunt on The Cancer Genome Atlas Project in Bladder Cancer
April 5th 2018Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses The Cancer Genome Atlas (TCGA) project in bladder cancer.
Read More
Dr. Bellmunt on Immunotherapy Combination Trials in Bladder Cancer
March 28th 2018Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses trials investigating combinations with immunotherapy for patients with bladder cancer.
Read More
Dr. Bellmunt on Immunotherapy Plus IDO in Urothelial Carcinoma
February 12th 2018Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses the combination of immunotherapy with IDO inhibitors for patients with urothelial carcinoma.
Read More
Dr. Bellmunt Discusses Follow-Up Data for Pembrolizumab vs Chemotherapy in Bladder Cancer
February 10th 2018Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses 2-year follow-up results from the phase III KEYNOTE-045 trial of pembrolizumab (Keytruda) versus chemotherapy in recurrent, advanced urothelial carcinoma during the 2018 Genitourinary Cancers Symposium.
Read More
Dr. Bellmunt Shares KEYNOTE-045 Data for Pembrolizumab Versus Chemotherapy in Bladder Cancer
November 13th 2016Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses findings from the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma.
Read More
Chemotherapy is Indicated, Yet Used Infrequently, in Patients With MIBC
A review by André P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.
Read More